- Home
- ICCM vs VRCA Comparison
ICCM vs VRCA Comparison
Compare ICCM & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- VRCA
- Stock Information
- Founded
- ICCM 2006
- VRCA 2013
- Country
- ICCM Israel
- VRCA United States
- Employees
- ICCM N/A
- VRCA N/A
- Industry
- ICCM
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- VRCA Health Care
- Exchange
- ICCM Nasdaq
- VRCA Nasdaq
- Market Cap
- ICCM 55.8M
- VRCA 54.0M
- IPO Year
- ICCM N/A
- VRCA 2018
- Fundamental
- Price
- ICCM $0.99
- VRCA $0.53
- Analyst Decision
- ICCM Strong Buy
- VRCA Hold
- Analyst Count
- ICCM 1
- VRCA 5
- Target Price
- ICCM $2.50
- VRCA $6.00
- AVG Volume (30 Days)
- ICCM 278.9K
- VRCA 427.9K
- Earning Date
- ICCM 08-19-2025
- VRCA 08-13-2025
- Dividend Yield
- ICCM N/A
- VRCA N/A
- EPS Growth
- ICCM N/A
- VRCA N/A
- EPS
- ICCM N/A
- VRCA N/A
- Revenue
- ICCM $3,273,000.00
- VRCA $7,179,000.00
- Revenue This Year
- ICCM $83.41
- VRCA $171.87
- Revenue Next Year
- ICCM $185.02
- VRCA $71.38
- P/E Ratio
- ICCM N/A
- VRCA N/A
- Revenue Growth
- ICCM 0.34
- VRCA N/A
- 52 Week Low
- ICCM $0.48
- VRCA $0.38
- 52 Week High
- ICCM $1.66
- VRCA $8.98
- Technical
- Relative Strength Index (RSI)
- ICCM 46.56
- VRCA 49.17
- Support Level
- ICCM $0.81
- VRCA $0.57
- Resistance Level
- ICCM $1.03
- VRCA $0.67
- Average True Range (ATR)
- ICCM 0.06
- VRCA 0.06
- MACD
- ICCM 0.01
- VRCA -0.01
- Stochastic Oscillator
- ICCM 75.00
- VRCA 14.73
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.